Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, et al. - The present analysis was conducted to assess the effectiveness and safety of sofosbuvir plus ribavirin for 12 weeks in children aged 3 to < 12 years chronically infected with genotype 2 or for 24 weeks in patients with genotype 3. For this open-label study, patients aged 3 to < 6 years weighing < 17 kg received sofosbuvir 150 mg, and patients aged 3 to < 6 years weighing ≥ 17 kg and all patients aged 6 to < 12 years received sofosbuvir 200 mg once daily. In children aged 3 to < 12 years with chronic HCV genotype 2 or 3 infection, sofosbuvir plus ribavirin was well tolerated and highly effective. Vomiting and headache were the most commonly reported adverse events in patients aged 6 to < 12 years, and vomiting and diarrhea were those in patients aged 3 to < 6 years.